comparemela.com

Latest Breaking News On - நுரையீரல் புற்றுநோய் பிறழ்வு கூட்டமைப்பு - Page 2 : comparemela.com

Längre progressionsfri överlevnad för patienter med HER2-positiv spridd bröstcancer som behandlats med Enhertu (trastuzumab deruxtecan)

Längre progressionsfri överlevnad för patienter med HER2-positiv spridd bröstcancer som behandlats med Enhertu (trastuzumab deruxtecan)
onkologiisverige.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onkologiisverige.se Daily Mail and Mail on Sunday newspapers.

LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate

 E-Mail (Singapore January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST) Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer s World Conference on Lung Cancer. Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results from a study of 181 patients with stage IB to IIIB non-small cell lung cancer (NSCLC) who each received 1,200 mg of neoadjuvant atezolizumab intravenously every three weeks for two cycles followed by resection. Atezolizumab is a monoclonal antibody that was approved by the US Food and Drug Administration in 2020 for the first-line treatment of adult patients with metastatic NSCLC.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.